Clinical Trial Update: Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating pegzilarginase in combination with pembrolizumab for extensive-disease small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Pegzilarginase (pegzilarginase)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Aeglea Biotherapeutics | Conditions: Small-cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED